Information  X 
Enter a valid email address

Verona Pharma PLC Ord 5P (VRP)

Date Time Source Announcement
21 Sep 2020 7:00 am
GNW
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM
17 Sep 2020 7:00 am
GNW
Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
16 Sep 2020 1:25 pm
GNW
Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease
08 Sep 2020 7:00 am
GNW
Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
02 Sep 2020 7:00 am
GNW
Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference
26 Aug 2020 10:19 am
GNW
Verona Pharma plc: Grant of RADSUs and PDMR Dealings
24 Aug 2020 7:00 am
GNW
Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020
19 Aug 2020 7:00 am
GNW
Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD
14 Aug 2020 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020
07 Aug 2020 3:46 pm
GNW
Verona Pharma plc: TR-1: Standard form for notification of major holdings
04 Aug 2020 6:13 pm
GNW
Verona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights
03 Aug 2020 7:00 am
GNW
Verona Pharma Announces August 2020 Virtual Investor Conference Participation
30 Jul 2020 10:52 am
GNW
Verona Pharma plc: TR-1: Standard form for notification of major holdings
  7:00 am
GNW
Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update
27 Jul 2020 7:01 am
GNW
Verona Pharma plc: TR-1: Standard form for notification of major holdings
22 Jul 2020 4:50 pm
GNW
Closing of Financing, Issued Share Capital and Total Voting Rights
17 Jul 2020 5:47 pm
GNW
Verona Pharma plc: PDMR Dealings
  7:00 am
GNW
Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
06 Jul 2020 4:04 pm
GNW
Verona Pharma plc: Issue of Equity and Total Voting Rights
14 May 2020 7:00 am
GNW
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
12 May 2020 1:11 pm
GNW
Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings
01 May 2020 5:12 pm
GNW
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
30 Apr 2020 7:00 am
GNW
Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020
23 Apr 2020 7:00 am
GNW
Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update
16 Apr 2020 12:12 pm
GNW
Verona Pharma plc: Results of AGM
08 Apr 2020 7:00 am
GNW
Update on AGM Procedure
31 Mar 2020 7:00 am
GNW
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
20 Mar 2020 11:28 am
GNW
Verona Pharma plc: Issue of Equity and Total Voting Rights
17 Mar 2020 2:06 pm
RNS
Second Price Monitoring Extn
  2:01 pm
RNS
Price Monitoring Extension
16 Mar 2020 5:13 pm
GNW
2019 Annual Report and Accounts and Notice of AGM
05 Mar 2020 4:01 pm
GNW
Grant of Restricted Stock Units and PDMR Dealings
27 Feb 2020 7:00 am
GNW
Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
21 Feb 2020 7:00 am
GNW
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
14 Feb 2020 7:00 am
GNW
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
07 Feb 2020 7:00 am
GNW
Holding(s) in Company TR-1: Standard form for notification of major holdings
28 Jan 2020 7:00 am
GNW
Verona Pharma to Present at LSX World Congress 2020
17 Jan 2020 1:06 pm
GNW
Holding(s) in Company TR-1: Standard form for notification of major holdings
13 Jan 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  5:00 am
GNW
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
10 Jan 2020 11:00 pm
GNW
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
07 Jan 2020 7:00 am
GNW
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations
28 Nov 2019 10:25 am
GNW
Holding(s) in Company TR-1: Standard form for notification of major holdings
27 Nov 2019 7:00 am
GNW
Verona Pharma plc: Grant of Options to PDMR
18 Nov 2019 7:00 am
GNW
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
14 Nov 2019 7:00 am
GNW
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
13 Nov 2019 7:00 am
GNW
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference
11 Nov 2019 7:00 am
GNW
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
05 Nov 2019 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
29 Oct 2019 7:00 am
GNW
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
17 Oct 2019 7:00 am
GNW
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
15 Oct 2019 7:00 am
GNW
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
19 Sep 2019 7:00 am
GNW
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
09 Sep 2019 2:33 pm
GNW
Holding(s) in Company TR-1: Standard form for notification of major holdings
09 Aug 2019 9:35 am
GNW
Verona Pharma plc: PDMR Dealing
06 Aug 2019 7:00 am
GNW
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
05 Aug 2019 7:00 am
GNW
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t